Seres Therapeutics, Inc.

Modernatx, Inc.

Seres Health, Inc.

John Grant Aunins

David Arthur Berry

David N Cook

Matthew R Henn

Geoffrey Von Maltzahn

Kevin Daniel Litcofsky

Anthony Mario D'Onofrio

Noubar Boghos Afeyan

Mary-Jane Lombardo McKenzie

Gregory McKenzie

Brian Goodman

Marin Vulic

Jonathan Winkler

Toshiro Kendrick Ohsumi

Mary-Jane Lombardo Mckenzie

William Joseph Issa

Han Zhang

Stephane Bancel

Tirtha Chakraborty

Joseph Louis Barberio

Anthony Mario D'onofrio

Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Synergistic bacterial compositions and methods of production and use thereof

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Disclosed herein are methods for purifying RNA comprising poly A. Also disclosed herein are compositions such as surfaces and oligonucleotides for purifying RNA comprising polyA. Other embodiments are also disclosed. Commercially-available resins having polythymidine oligonucleotide ligands typically contain less than 30 thymidine (2′deoxy) residues and some commercial resin suppliers utilize a distribution of dT chain lengths, not of a discreet length.

Ribonucleic acid purification

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.

Network-based microbial compositions and methods

Provided are therapeutic compositions containing Ecobiotic&#x2122; populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Disclosed herein are methods for purifying RNA comprising poly A. Also disclosed herein are compositions such as surfaces and oligonucleotides for purifying RNA comprising polyA. Other embodiments are also disclosed. Commercially-available resins having polythymidine oligonucleotide ligands typically contain less than 30 thymidine (2'deoxy) residues and some commercial resin suppliers utilize a distribution of dT chain lengths, not of a discreet length.

Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients.

Growing community of inventors

Doylestown, PA, United States of America

John Grant Aunins